Human lymphoblastoid interferon for the treatment of chronic hepatitis B. A randomized controlled trial. 1988

G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
Clinica Medica I e Gastroenterologia, University of Bologna, Italy.

The aim of this study was to demonstrate whether interferon alone could affect the course of chronic hepatitis B. A total of 66 patients have so far been randomly assigned to receive six months of interferon therapy or no therapy; three patients in the interferon group and two in the control group have withdrawn from the study. Loss of hepatitis B virus-DNA and hepatitis B e antigen was significantly higher in the patients receiving interferon than in the control group; a significant loss of hepatitis B surface antigen was observed only in patients who received interferon. The time to alanine aminotransferase normalization was significantly shorter in patients receiving interferon than in the control group. These data encourage the use of interferon in treatment of chronic hepatitis B.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B

Related Publications

G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
May 1987, Gut,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
January 1986, Journal of hepatology,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
September 2001, Hepatology research : the official journal of the Japan Society of Hepatology,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
January 2006, Antiviral therapy,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
April 1992, Hepatology (Baltimore, Md.),
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
January 1989, BMJ (Clinical research ed.),
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
February 1993, The American journal of gastroenterology,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
February 1994, Journal of hepatology,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
January 1986, Journal of hepatology,
G Mazzella, and G Saracco, and M Rizetto, and M A Amed, and A Gonzàlez Quintela, and F Rosina, and L Barbara, and E Roda
May 1997, Journal of viral hepatitis,
Copied contents to your clipboard!